| |
| |
|
| Insider
Information: |
Menzel Garry E |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
99,875 |
|
|
Indirect Shares
|
364,314 |
|
|
| Direct
Value |
$226,869 |
|
|
|
Indirect Value
|
$791,602 |
|
|
| Total
Shares |
464,189 |
|
|
| Total
Value |
$1,018,472 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 63.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regulus Therapeutics Inc. |
RGLS |
Officer |
|
0 |
2012-10-04 |
111,842 |
Premium* |
|
|
Black Diamond Therapeutics, Inc. |
BDTX |
Director |
2020-01-29 |
24,819 |
2020-02-03 |
51,825 |
Premium* |
|
|
Tcr2 Therapeutics Inc. |
TCRR |
President and CEO, Dir... |
2023-06-01 |
0 |
2023-06-01 |
0 |
Premium* |
|
|
Adaptimmune Therapeutics PLC |
ADAP |
Director |
2023-07-10 |
75,056 |
2023-06-01 |
200,647 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ADAP |
Adaptimmune Therapeutics ... |
Director |
– • – |
2023-07-10 |
4 |
S |
$0.91 |
$43,447 |
D/D |
(47,702) |
75,056 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President and CEO |
• • – |
2023-06-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(138,871) |
0 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President and CEO |
• • – |
2023-06-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(265,459) |
0 |
0 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
209,931 |
209,931 |
0 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
I/I |
401,293 |
200,647 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President and CEO |
• • – |
2022-12-13 |
4 |
AS |
$1.06 |
$11,682 |
D/D |
(11,000) |
138,871 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President and CEO |
• • – |
2022-12-12 |
4 |
AS |
$1.10 |
$11,674 |
D/D |
(10,613) |
149,871 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President and CEO |
• • – |
2022-12-09 |
4 |
AS |
$1.13 |
$11,678 |
D/D |
(10,325) |
160,484 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President and CEO |
• • – |
2022-12-08 |
4 |
AS |
$1.25 |
$11,680 |
D/D |
(9,314) |
170,809 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President and CEO |
• • – |
2022-12-07 |
4 |
AS |
$1.28 |
$11,680 |
D/D |
(9,111) |
180,123 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President and CEO |
• • – |
2022-12-06 |
4 |
AS |
$1.35 |
$20,081 |
D/D |
(14,886) |
189,234 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President and CEO |
• • – |
2022-12-05 |
4 |
AS |
$1.37 |
$11,703 |
D/D |
(8,530) |
204,120 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President & CEO |
• • – |
2022-12-02 |
4 |
AS |
$1.39 |
$11,687 |
D/D |
(8,408) |
212,650 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President & CEO |
• • – |
2022-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
221,058 |
221,058 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President & CEO |
• • – |
2022-07-05 |
4 |
GA |
$0.00 |
$0 |
I/I |
265,459 |
132,730 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President & CEO |
• • – |
2022-07-05 |
4 |
GD |
$0.00 |
$0 |
D/D |
180,932 |
0 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President & CEO |
• • – |
2022-07-05 |
4 |
GD |
$0.00 |
$0 |
I/I |
84,527 |
0 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President & CEO |
• • – |
2022-02-28 |
4 |
A |
$2.30 |
$3,278 |
D/D |
1,425 |
180,932 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President & CEO |
• • – |
2021-12-09 |
4 |
OE |
$0.74 |
$129,500 |
D/D |
175,000 |
179,507 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President & CEO |
• • – |
2021-08-31 |
4 |
A |
$14.26 |
$6,018 |
D/D |
422 |
4,507 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President and CEO |
• • – |
2021-02-28 |
4 |
A |
$16.12 |
$11,061 |
D/D |
686 |
4,085 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President and CEO |
• • – |
2020-08-31 |
4 |
A |
$10.10 |
$11,431 |
D/D |
1,132 |
3,399 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
President & CEO |
• • – |
2020-02-28 |
4 |
A |
$10.10 |
$12,999 |
D/D |
1,287 |
2,267 |
0 |
- |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
I/I |
51,825 |
51,825 |
0 |
- |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • – |
2020-01-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
24,819 |
|
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
